AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
![]() ![]() "Obesity is a chronic, treatable disease, and individuals living with obesity deserve effective and safe treatment options that can help restore their weight to levels that support optimal health," said Ania Jastreboff, MD, Ph.D., Associate Professor of Medicine & Pediatrics, Endocrinology & Metabolism, at Yale School of Medicine Director, Weight Management & Obesity Prevention at the Yale Stress Center and co-Director of the Yale Center for Weight Management. Participants taking tirzepatide also achieved an approximately three times greater percent reduction in fat mass versus lean mass (33.9% fat mass reduction compared to a 10.9% lean mass reduction). Change in waist circumference from baseline: -14.6 cm (5 mg, not controlled for type 1 error), ‑19.4 cm (10 mg) and -19.9 cm (15 mg) compared to -3.4 cm with placebo.Īll three doses of tirzepatide achieved an additional secondary endpoint at 72 weeks of treatment, measuring the percentage of participants achieving at least 25% body weight reductions (not controlled for type 1 error): 16.5% (5 mg), 35% (10 mg) and 39.7% (15 mg) compared to 0.3% with placebo.Percentage of participants achieving at least 20% body weight reductions: 32% (5 mg, not controlled for type 1 error), 55% (10 mg) and 63% (15 mg) compared to 1.3% with placebo.Percentage of participants achieving at least 15% body weight reductions: 50% (5 mg, not controlled for type 1 error), 74% (10 mg) and 78% (15 mg) compared to 6.0% with placebo.Percentage of participants achieving at least 10% body weight reductions: 73% (5 mg, not controlled for type 1 error), 86% (10 mg) and 90% (15 mg) compared to 14% with placebo.Additionally, 89% (5 mg) and 96% (10 mg and 15 mg) of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo.Īll three doses of tirzepatide achieved all key secondary endpoints at 72 weeks of treatment for the efficacy estimand, including: or 24 kg on 15 mg), compared to placebo (2.4%, 5 lb. Tirzepatide met both co-primary endpoints of superior mean percent change in body weight from baseline and greater percentage of participants achieving body weight reductions of at least 5% compared to placebo for both estimands i.įor the efficacy estimand ii, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. ![]() INDIANAPOLIS, J/PRNewswire/ - Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or overweight were simultaneously published today in The New England Journal of Medicine (NEJM) and presented in a symposium sponsored by the American Diabetes Association ® (ADA) during the ADA's 82 nd Scientific Sessions ®. Detailed results from Lilly's first phase 3 trial in obesity or overweight presented at the American Diabetes Association's ® 82 nd Scientific Sessions ® and simultaneously published in NEJM ![]()
0 Comments
Read More
Leave a Reply. |